DT&CRO, Public Offering Price Set at 17,000 Won... Competition Rate 74.53 to 1

[Asia Economy Reporter Jang Hyowon] Full-service CRO company DTN CRO (CEO Park Chaekyu) announced on the 1st that it has set the public offering price at 17,000 KRW. It plans to offer 1.4 million shares worth a total of 23.8 billion KRW, and the expected market capitalization immediately after listing is approximately 107.3 billion KRW. Subscription for general investors will be conducted over two days on the 2nd and 3rd, with trading scheduled to begin on the KOSDAQ market on the 11th.

Previously, during the demand forecast held over two days on October 26-27, a total of 461 institutions participated, recording a competition rate of 74.53 to 1. A representative from Kiwoom Securities, which underwrote the listing, explained, “We believe that DTN CRO’s growth potential and differentiation as a full-service CRO were recognized, but we agreed that increasing shareholder value after listing is more important, which influenced the decision on the public offering price.”

DTN CRO is the only domestic CRO company capable of providing full-service from non-clinical trials including efficacy and toxicity tests to Phase 1 clinical trials. In particular, it showcases a differentiated process enabled by the combination of Biotechnology (BT) and Information Technology (IT).

Park Chaekyu, CEO of DTN CRO, emphasized, “We are grateful to those who recognized DTN CRO’s potential and invested, and we will operate in a way that definitely returns profits. After listing, we will focus on securing a stronger market share in various fields of non-clinical, clinical, and analytical services through the funds raised.”

This content was produced with the assistance of AI translation services.